Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Addressing antibiotic resistance.

Kalpana Gupta

    Disease-A-Month : DM
    |February 26, 2003
    PubMed
    Summary
    This summary is machine-generated.

    Rising antibiotic resistance to trimethoprim-sulfamethoxazole (TMP-SMX) impacts uncomplicated urinary tract infections (UTIs). Treatment guidelines must adapt, considering local resistance rates for effective empiric therapy. Alternative antibiotics may be necessary.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    An education with audit and targeted feedback intervention to de-implement preoperative surgical urine cultures: a multi-center quasi-experimental study.

    Infection control and hospital epidemiology·2026
    Same author

    Activity in barrel cortex related to tactile delay eyeblink conditioning.

    Cerebral cortex (New York, N.Y. : 1991)·2026
    Same author

    Renovating the Barnes maze for mouse models of dementia with STARR FIELD: A 4-day protocol for learning rate, retention, and cognitive flexibility.

    Methods (San Diego, Calif.)·2026
    Same author

    State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
    Same author

    Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Introduction and Methods.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
    Same author

    Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025

    Area of Science:

    • Infectious Diseases
    • Pharmacology
    • Urology

    Background:

    • Uncomplicated urinary tract infections (UTIs) traditionally managed with predictable bacterial susceptibility.
    • Trimethoprim-sulfamethoxazole (TMP-SMX) was a standard empiric therapy for cystitis due to predictable efficacy.
    • Increasing antibiotic resistance is a growing concern for both complicated and uncomplicated UTIs.

    Purpose of the Study:

    • To evaluate the impact of rising antibiotic resistance on the management of uncomplicated UTIs.
    • To assess the current efficacy of trimethoprim-sulfamethoxazole (TMP-SMX) in light of increasing resistance.
    • To recommend changes in empiric therapy guidelines for community-acquired UTIs.

    Main Methods:

    • Review of existing literature on UTI epidemiology and antibiotic resistance patterns.

    Related Experiment Videos

  • Analysis of resistance trends for common UTI pathogens, including Escherichia coli and Staphylococcus saprophyticus.
  • Comparison of resistance rates for various antibiotic classes, including TMP-SMX, nitrofurantoin, and fluoroquinolones.

    • Main Results:

    • Resistance to TMP-SMX in some US regions approaches 18-22%, with nearly 33% resistance to amoxicillin.
    • Resistance to nitrofurantoin and fluoroquinolones remains low at approximately 2%.
    • Emerging data links TMP-SMX resistance to poorer treatment outcomes.

    Conclusions:

    • The rise in TMP-SMX resistance necessitates a shift in empiric UTI management strategies.
    • TMP-SMX use as first-line therapy is only advised in regions with <10-20% resistance.
    • Alternative antibiotic agents should be considered where TMP-SMX resistance exceeds recommended thresholds.